Simplify myeloid malignancy profiling with NGS One comprehensive assay for all relevant DNA mutations and fusion transcripts.

Brought to you by ThermoFisher Scientific

Myeloid malignancies are complex and highly heterogeneous diseases with many subtypes and oncogenic drivers in play. Sequential approaches for analyzing myeloid malignancies can be laborious and time consuming. As the number of relevant biomarkers continues to grow, a more streamlined approach is needed to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers. Next-generation sequencing (NGS) with the Oncomine Myeloid Research Assay is an optimal solution, enabling comprehensive assessment of all relevant molecular markers in a single test.

Hear what our customers have to say about the Oncomine Myeloid Research Assay

Dr. Michael Rauh from Queen's University discusses the role and impact of NGS for profling myeloid malignancies such as AML and MDS.

Dr. Bekim Sadikovic discusses how they can assess a range of variants for myeloid malignancies using a single assay

A single comprehensive, targeted NGS assay for myeloid cancers


  • Covers 40 key DNA target genes, 29 driver genes, and a broad fusion panel
  • Spans the entire spectrum of major myeloid disorders, including acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Comprehensive coverage. Complete efficiency.

Allergy Testing

Gain Efficiency

Simultaneously interrogate all relevant DNA mutations and fusion transcripts associated with myeloid malignancies

Allergy Testing

Accelerate Insight

Get your answer in as few as 2 days.

Allergy Testing

Detect Challenging Targets

Gain critical insights with dedicated FLT3-ITD detection software & excellent coverage of challenging targets such as CEBPA.

Webinar: Implementing Targeted NGS in Myeloid Malignancies

Hear from Dr. Nancy Carson, Head of the Division of Genetics at the Saint John Regional Hospital, as she discusses:

  • Unique considerations and applications of NGS in myeloid malignancies
  • Overview of her experience with analytical validation and implementation of the Ion Torrent Oncomine Myeloid Assay
  • Impact of the implementation of the assay to date and future directions

Learn More

To learn more about the Oncomine Myeloid Research Assay, visit the product web page on Here you will find additional product details about the assay and overall workflow solution


For Research Use Only. Not for use in diagnostic procedures.